Molecular landscape of prDLBCL. (A) Venn diagram depicting the number of samples for which whole-exome sequencing (WES; n = 26), RNA-seq (n = 29), and OncoScan (n = 29) were successfully performed. (B) Fusions identified by RNA-seq in prDLBCL samples (beyond MYC/BCL2/BCL6 rearrangements identified in cases studied by fluorescence in situ hybridization [FISH]) displayed by their genomic location. (C) Sankey plot illustrating the distribution of cases of prDLBCL into GCB/non-GCB categories by IHC according to the algorithm proposed by Hans et al¹¹ as well as by COO classified according to gene expression profiling derived from RNA-seq and lastly according to molecular clusters drawn from the LymphGen algorithm, integrating data from WES, RNA-seq, OncoScan, and FISH (BCL2/BCL6/MYC), depicting the significant degree of molecular heterogeneity. (D) Oncoplot displaying putative driver genes and the number of samples harboring mutations in a given gene (right). Mutation types are color coded, and covariates, including sex, COO, FISH results for BCL2/BCL6/MYC, and type of biopsy (punch/needle core vs open resection/nephrectomy), are shown below for each sample. COO, cell of origin; EBV, Epstein-Barr-Virus; f, female; IHC, immunohistochemistry; m, male; NA, not available.